Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis

Molecular Pharmaceutics

Volumn 9, Issue 5, 2012, Pages 1310-1319

  Hong, Sungchae ^a   Yum, Soohwan ^a   Yoo, Hyun Jung ^a   Kang, Sookjin ^a   Yoon, Jeong Hyun ^a   Min, Dosik ^a   Kim, Young Mi ^a   Jung, Yunjin ^a  

^a Pusan National University   (South Korea)

Author keywords

cell permeable peptide; colitis; colon targeted delivery; nuclear factor kappaB

Indexed keywords

CELL PENETRATING PEPTIDE; CELL PERMEABLE PEPTIDE CONJUGATED NUCLEAR FACTOR KAPPA B INHIBITORY PEPTIDE; CYTOPLASMIC TRANSDUCTION PEPTIDE CONJUGATED NEMO BINDING DOMAIN PEPTIDE; I KAPPA B; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SN 50; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; COLITIS; COLON; COLON INJURY; CONTROLLED STUDY; DRUG CAPSULE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CACO-2 CELLS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; COLON; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; IRRITABLE BOWEL SYNDROME; MALE; NF-KAPPA B; PEPTIDES; RATS; TRINITROBENZENESULFONIC ACID;

EID: 84860720700     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200591q     Document Type: Article

References (28)

1. Abraham, C.; Cho, J. H. Inflammatory bowel disease N. Engl. J. Med. 2009, 361 (21) 2066-2078
2. Li, Q.; Verma, I. M. NF-kappaB regulation in the immune system Nat. Rev. Immunol. 2002, 2 (10) 725-734
3. Neurath, M. F.; Becker, C.; Barbulescu, K. Role of NF-kappaB in immune and inflammatory responses in the gut Gut 1998, 43 (6) 856-860
4. Neurath, M. F.; Fuss, I.; Schurmann, G.; Pettersson, S.; Arnold, K.; Muller-Lobeck, H.; Strober, W.; Herfarth, C.; Buschenfelde, K. H. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease Ann. N.Y. Acad. Sci. 1998, 859, 149-159
5. Atreya, I.; Atreya, R.; Neurath, M. F. NF-kappaB in inflammatory bowel disease J. Intern. Med. 2008, 263 (6) 591-596
6. Rutgeerts, P.; Van Assche, G.; Vermeire, S. Optimizing anti-TNF treatment in inflammatory bowel disease Gastroenterology 2004, 126 (6) 1593-1610
7. Dave, S. H.; Tilstra, J. S.; Matsuoka, K.; Li, F.; Karrasch, T.; Uno, J. K.; Sepulveda, A. R.; Jobin, C.; Baldwin, A. S.; Robbins, P. D.; Plevy, S. E. Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide J. Immunol. 2007, 179 (11) 7852-7859
8. Shibata, W.; Maeda, S.; Hikiba, Y.; Yanai, A.; Ohmae, T.; Sakamoto, K.; Nakagawa, H.; Ogura, K.; Omata, M. Cutting edge: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis J. Immunol. 2007, 179 (5) 2681-2685
9. Lambkin, I.; Pinilla, C. Targeting approaches to oral drug delivery Expert Opin. Biol. Ther. 2002, 2 (1) 67-73
10. Mahato, R. I.; Narang, A. S.; Thoma, L.; Miller, D. D. Emerging trends in oral delivery of peptide and protein drugs Crit. Rev. Ther. Drug Carrier Syst. 2003, 20 (2-3) 153-214
11. Morishita, M.; Peppas, N. A. Is the oral route possible for peptide and protein drug delivery? Drug Discovery Today 2006, 11 (19-20) 905-910
12. Brooks, H.; Lebleu, B.; Vives, E. Tat peptide-mediated cellular delivery: back to basics Adv. Drug Delivery Rev. 2005, 57 (4) 559-577
13. Gupta, B.; Levchenko, T. S.; Torchilin, V. P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides Adv. Drug Delivery Rev. 2005, 57 (4) 637-651
14. Kamei, N.; Morishita, M.; Eda, Y.; Ida, N.; Nishio, R.; Takayama, K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption J. Controlled Release 2008, 132 (1) 21-25
15. Liang, J. F.; Yang, V. C. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency Biochem. Biophys. Res. Commun. 2005, 335 (3) 734-738
16. Sinha, V.; Singh, A.; Kumar, R. V.; Singh, S.; Kumria, R.; Bhinge, J. Oral colon-specific drug delivery of protein and peptide drugs Crit. Rev. Ther. Drug Carrier Syst. 2007, 24 (1) 63-92
17. Jung, Y.; Kim, Y. M. What should be considered on design of a colon-specific prodrug? Expert Opin. Drug Delivery 2010, 7 (2) 245-258
18. Kim, D.; Jeon, C.; Kim, J. H.; Kim, M. S.; Yoon, C. H.; Choi, I. S.; Kim, S. H.; Bae, Y. S. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo Exp. Cell. Res. 2006, 312 (8) 1277-1288
19. Lin, Y. Z.; Yao, S. Y.; Veach, R. A.; Torgerson, T. R.; Hawiger, J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence J. Biol. Chem. 1995, 270 (24) 14255-14258
20. Takada, Y.; Singh, S.; Aggarwal, B. B. Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis J. Biol. Chem. 2004, 279 (15) 15096-15104
21. May, M. J.; D'Acquisto, F.; Madge, L. A.; Glockner, J.; Pober, J. S.; Ghosh, S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex Science 2000, 289 (5484) 1550-1554
22. Yamaoka, T.; Makita, Y.; Sasatani, H.; Kim, S. I.; Kimura, Y. Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: its properties, degradation behavior, and utilization for drug formulation J. Controlled Release 2000, 66 (2-3) 187-197
23. Morris, G. P.; Beck, P. L.; Herridge, M. S.; Depew, W. T.; Szewczuk, M. R.; Wallace, J. L. Hapten-induced model of chronic inflammation and ulceration in the rat colon Gastroenterology 1989, 96 (3) 795-803
24. Prochiantz, A. Protein and peptide transduction, twenty years later a happy birthday Adv. Drug Delivery Rev. 2008, 60 (4-5) 448-451
25. Nam, N. H. Naturally occurring NF-kappaB inhibitors Mini-Rev. Med. Chem. 2006, 6 (8) 945-951
26. Trehin, R.; Krauss, U.; Beck-Sickinger, A. G.; Merkle, H. P.; Nielsen, H. M. Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat(47-57) through well-differentiated epithelial models Pharm. Res. 2004, 21 (7) 1248-1256
27. Fiocchi, C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions Am. J. Physiol. 1997, 273 (4 Part 1) G769-G775
28. Canani, R. B.; Cirillo, P.; Mallardo, G.; Buccigrossi, V.; Secondo, A.; Annunziato, L.; Bruzzese, E.; Albano, F.; Selvaggi, F.; Guarino, A. Effects of HIV-1 Tat protein on ion secretion and on cell proliferation in human intestinal epithelial cells Gastroenterology 2003, 124 (2) 368-376